Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors

ConclusionThe PPK model adequately described rucaparib PK, and none of the covariates evaluated had a clinically relevant effect.ClinicalTrials.govStudy 1014 (NCT01009190), Study 10 (NCT01482715), ARIEL2 (NCT01891344), ARIEL3 (NCT01968213), and TRITON2 (NCT02952534).
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research